Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Multinational, Randomized, Controlled, Assessor Blinded Study, Performed in Subjects With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid Compared to Gel Vehicle and Compared to Standard of Care

Next Previous
Trial Profile

A Multicenter, Multinational, Randomized, Controlled, Assessor Blinded Study, Performed in Subjects With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid Compared to Gel Vehicle and Compared to Standard of Care

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bromelains (Primary) ; Bromelains (Primary) ; Collagenase
  • Indications Burns
  • Focus Registrational; Therapeutic Use
  • Acronyms DETECT
  • Sponsors MediWound

    • Most Recent Events

    • 28 Sep 2023 According to a Vericel Corporation media release, results of this study assessing the safety and efficacy of NexoBrid (anacaulase-bcdb) published in the Journal of Burn Care & Research.
    • 28 Sep 2023 Results presented in the Vericel Corporation media release.
    • 09 May 2023 According to Mediwound media release, BRADA has provided technical assistance and a total funding of $98 million for Nexobird development activities. Amongst the development activities this study is one of the agenda.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top